Zanamivir aqueous solution in severe influenza: A global Compassionate Use Program, 2009-2019.

ABSTRACT:

Background

Zanamivir is a neuraminidase inhibitor effective against influenza A and B viruses. In 2009, GlaxoSmithKline (GSK) began clinical development of intravenous (IV) zanamivir and initiated a global Compassionate Use Program (CUP) in response to the evolving H1N1 global pandemic. The goal of the CUP was to provide zanamivir to critically ill patients with limited treatment options.

Methods

Zanamivir was administered to patients with suspected or confirmed influenza infection who were not suitable for other approved antiviral treatments. Reporting of serious adverse events (SAEs) was mandatory and recorded in the GSK safety database. A master summary tracking sheet captured requests and patient characteristics. A case report form was available for detailing medical con

SUBMITTER: Wang-Jairaj J 

PROVIDER: S-EPMC8983904 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature